Dynamic Hyperinflation and Tiotropium
This study has been completed.
Sponsor:
Gelb, Arthur F., M.D.
Collaborators:
Boehringer Ingelheim Pharmaceuticals
Pfizer
Information provided by (Responsible Party):
Gelb, Arthur F., M.D.
ClinicalTrials.gov Identifier:
NCT00569270
First received: December 6, 2007
Last updated: October 4, 2012
Last verified: October 2012
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
We will detect dynamic hyperinflation (DH) in 40 COPD (chronic obstructive pulmonary disease) patients with moderately severe disease using metronome paced hyperventilation (MPH) with inspiratory capacity as the primary end point. Hypothesis: Is tiotropium capable of lung volume protecting inspiratory capacity from MPH induced DH vs placebo in a randomized crossover double blinded study.
| Condition | Intervention | Phase |
|---|---|---|
|
COPD |
Drug: tiotropium Drug: placebo |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Crossover Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | Simplified Detection of Dynamic Hyperinflation Using Metronome Paced Hyperventilation and the Effect of Tiotropium in Patients With COPD |
Resource links provided by NLM:
Further study details as provided by Gelb, Arthur F., M.D.:
Primary Outcome Measures:
- Bronchodilator Response:Peak FEV1(L)(Forced Expiratory Volume in One Second)- [ Time Frame: 30 days ] [ Designated as safety issue: No ]Lung function studies (mean +/- SD): peak FEV1 (+2h) after 30 days of placebo or tiotropium in 29 moderate COPD patients. FEV1 = Forced expiratory volume in one second
- Bronchodilator Response:Peak FRC (L) (Functional Residual Capacity) [ Time Frame: 30 days ] [ Designated as safety issue: No ]Lung function studies (mean +/- SD): peak FRC after 30 days (+2h) of placebo or tiotropium in 29 moderate COPD patients.
- Bronchodilator Response: Peak FVC (L) (Forced Vital Capacity)- Tiotropium and Placebo [ Time Frame: 30 days ] [ Designated as safety issue: No ]Lung function studies (mean +/- SD) of peak forced vital capaciy (L) after 30 days (+2h) of tiotropium versus placebo in 29 moderate COPD patients. Forced vital capacity - liters
- Bronchodilator Response: Peak IC (L) - (Inspiratory Capacity) - Tiotropium Versus Placebo [ Time Frame: 30 days ] [ Designated as safety issue: No ]Lung function studies (mean +/- SD) - Peak inspiratory capacity after 30 days (+2h)of tiotropium versus placebo in 29 moderate COPD patients. Inspiratory capacity- liters
- Bronchodilator Response: Peak FRC/TLC Percentage (Functional Residual Capacity(L)/Total Lung Capacity(L) - Tiotropium or Placebo [ Time Frame: 30 days ] [ Designated as safety issue: No ]Lung function studies (mean +/- SD) peak Peak FRC/TLC after 30 days (+2h)of tiotropium versus placebo in 29 moderate COPD patients. Functional residual capacity/total lung capacity - percentage
- Bronchodilator Response: Peak TLC (L) (Total Lung Capacity)- Tiotropium or Placebo [ Time Frame: 30 days ] [ Designated as safety issue: No ]Net change in lung function studies (mean +/- SE) from baseline to trough (-1h) and peak (+2h) after 30 days of tiotropium versus placebo in 29 moderate COPD patients. Total lung capacity - liters
- Bronchodilator Response: Trough FEV1 (L)- (Forced Expiratory Volume) Tiotropium Versus Placebo [ Time Frame: 30 days ] [ Designated as safety issue: No ]Lung function studies Trough FEV1(mean +/- SD) after 30 days(-1h) of tiotropium versus placebo in 29 moderate COPD patients. Forced expiratory volume in 1s (liters)
- Bronchodilator Response: Trough FRC (L)- Tiotropium Versus Placebo [ Time Frame: 30 days ] [ Designated as safety issue: No ]Lung function studies Trough FRC(mean +/- SD) after 30 days(-1h) of tiotropium versus placebo in 29 moderate COPD patients. Functional residual capacity(liters)
- Bronchodilator Response: Trough FVC (L)- (Forced Vital Capacity) Tiotropium Versus Placebo [ Time Frame: 30 days ] [ Designated as safety issue: No ]Lung function studies Trough FVC(mean +/- SD) after 30 days(-1h) of tiotropium versus placebo in 29 moderate COPD patients
- Bronchodilator Response: Trough IC (L) Inspiratory Capacity - Tiotropium Versus Placebo [ Time Frame: 30 days ] [ Designated as safety issue: No ]Lung function studies (Trough IC(mean +/- SD) after 30 days(-1h) of tiotropium versus placebo in 29 moderate COPD patients Trough inspiratory capacity- liters
- Bronchodilator Response: Trough FRC/TLC (Functional Residual Capacity/Total Lung Capacity)- Tiotropium Versus Placebo [ Time Frame: 30 days ] [ Designated as safety issue: No ]Lung function studies Trough FRC/TLC(mean +/- SD) after 30 days(-1h) of tiotropium versus placebo in 29 moderate COPD patients Trough Functional residual capacity/total lung capacity - percentage
- Bronchodilator Response: Trough TLC (L) (Total Lung Capacity)- Tiotropium Versus Placebo [ Time Frame: 30 days ] [ Designated as safety issue: No ]Lung function studies Trough TLC(mean +/- SD) after 30 days(-1h) of tiotropium versus placebo in 29 moderate COPD patients
- IC (Inspiratory Capacity L)and Metronome Paced Hyperventilation-induced Dynamic Hyperinflation in Tiotropium Cohort Versus Placebo and Baseline [ Time Frame: baseline and 30 days (+2h) post dose ] [ Designated as safety issue: No ]IC measurement before and after metronome paced hyperventilation-induced dynamic hyperinflation at baseline and in tiotropium and placebo groups. Measure ratio of functional residual capacity divided by total lung capacity at baseline and after 30 days of tiotropium versus placebo
- TLC (L) Before and After Metronome Paced Hyperventilation Induced Dynamic Hyperinflation in Tiotropium Cohort Versus Placebo [ Time Frame: one hour before intervention & 2 hrs. after after 30 days ] [ Designated as safety issue: No ]Total lung capacity before and after metronome paced hyperventilation induced dynamic hyperinflation in tiotropium cohort versus placebo. Difference between TLC measured at one hour before intervention & 2 hrs. after after 30 days of treatment with either placebo or tiotropium
Secondary Outcome Measures:
- Extent of Lung CT Scored Emphysema and and Lung Function of FEV1(l) After Tiotropium [ Time Frame: baseline to 30 days ] [ Designated as safety issue: No ]Correlation between improved lung function after tiotropium and extent of lung CT scored emphysema with respect to FEV 1; correlation of tiotropium induced bronchodilation and extent of lung ct scored emphysema; measures include increase in FEV1 from baseline to peak tiotropium
- IC (Inspiratory Capacity, L) Post Mph (Metronome Paced Hyperventilation) Induced dh (Dynamic Hyperinflation) After Tiotropium and Extent of Lung CT Scored Emphysema [ Time Frame: baseline to 30 days ] [ Designated as safety issue: No ]Correlation between change in inspiratory capacity (L) post metronome paced hyperventilation induced dynamic hyperinflation and extent of lung ct scored emphysema
- Extent of Lung CT Scored Emphysema and and Lung Function of FRC/TLC (Functional Residual Capacity(L)/Total Lung Capacity (L) After Tiotropium [ Time Frame: baseline to trough tiotropium ] [ Designated as safety issue: No ]Correlation between improved lung function after tiotropium and extent of lung CT scored emphysema with respect to ratio functional residual capacity divided by total lung capacity. Specifically, correlation of tiotropium induced bronchodilation and extent of lung ct scored emphysema
| Enrollment: | 30 |
| Study Start Date: | October 2006 |
| Study Completion Date: | March 2009 |
| Primary Completion Date: | February 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: Tiotropium 18 µg capsule, bronchodilator
tiotropium 18 µg capsule for 1 month versus placebo. To study bronchodilation and effect following metronome paced hyperventilation and induced dynamic hyperinflation of active tiotropium versus placebo
|
Drug: tiotropium
Procedure/Surgery - tiotropium 18ug capsule daily for 1 month vs placebo to study the effect of trough and peak effect on bronchodilation and effect of metronome paced hyperventilation induced dynamic hyperinflation
Other Name: Spiriva
Drug: tiotropium
daily tiotropium 18ug versus daily placebo for 30 days
Other Name: Spiriva
|
|
Placebo Comparator: 2
placebo 18ug tiotropium for 1 month
|
Drug: tiotropium
Procedure/Surgery - tiotropium 18ug capsule daily for 1 month vs placebo to study the effect of trough and peak effect on bronchodilation and effect of metronome paced hyperventilation induced dynamic hyperinflation
Other Name: Spiriva
Drug: placebo
18ug tiotropium placebo capsule daily for 1 month
Drug: tiotropium
daily tiotropium 18ug versus daily placebo for 30 days
Other Name: Spiriva
|
Detailed Description:
Study completed with 29 patients studied. Data is being analyzed to evaluate trough and peak effect of 18 µg tiotropium vs placebo on FEV 1 (L)(forced expiratory capacity in one second), inspiratory capacity and functional residual volume. In addition, we will study the effect of 18 µg tiotropium vs placebo on metronome paced hyperventilation induced dynamic hyperinflation. We will also evaluate the effect of tiotropium induced increase in IC (inspiratory capacity) vs extent of emphysema as evaluated on high resolution thin section CT lung
Eligibility| Ages Eligible for Study: | 40 Years to 85 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Moderately severe COPD patients age 40-85 yr with post 180ug albuterol FEV 1 between 60 and 79% predicted and FEV 1/FVC < 70%.
- Smoking history > 10 pack yr.
- Clinically stable X 6 weeks.
- No oxygen usage.
Exclusion Criteria:
- History of asthma
- Clinically unstable
- Any other significant medical problem precluding full cooperation for study
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00569270
Locations
| United States, California | |
| Arthur F Gelb MD | |
| Lakewood, California, United States, 90712 | |
| Canada, Ontario | |
| Noe Zamel MD | |
| Toronto, Ontario, Canada | |
Sponsors and Collaborators
Gelb, Arthur F., M.D.
Boehringer Ingelheim Pharmaceuticals
Pfizer
Investigators
| Principal Investigator: | Arthur F Gelb, MD | Arthur F Gelb Medical Corporation |
| Principal Investigator: | Noe Zamel, MD | Mt. Sinai Hosp. Toronto, Univ Toronto Medical Center |
More Information
Publications:
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Gelb, Arthur F., M.D. |
| ClinicalTrials.gov Identifier: | NCT00569270 History of Changes |
| Other Study ID Numbers: | 20061693, IIS Boehringer-Ingelheim, IIS Pfizer |
| Study First Received: | December 6, 2007 |
| Results First Received: | August 20, 2011 |
| Last Updated: | October 4, 2012 |
| Health Authority: | United States: Institutional Review Board |
Additional relevant MeSH terms:
|
Pulmonary Disease, Chronic Obstructive Lung Diseases, Obstructive Lung Diseases Respiratory Tract Diseases Tiotropium Parasympatholytics Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs |
Pharmacologic Actions Cholinergic Antagonists Cholinergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Bronchodilator Agents Anti-Asthmatic Agents Respiratory System Agents Therapeutic Uses |
ClinicalTrials.gov processed this record on May 22, 2013